Ubrogepant - Uses, Side Effects, and Precautions

Introduction

Ubrogepant was approved by the FDA (Food and Drug Administration) for use in people with aura-free episodes of migraine in December 2019. You know that it is the first orally available calcitonin gene-related peptide (CGRP) receptor antagonist. Many small-molecule CGRP (calcitonin gene-related peptide) receptor antagonists were under investigation for migraines. The drugs used earlier were efficacious but had liver toxicity as a side effect. This followed the development of Ubrogepant, a hepatotoxicity-free alternative medicine. It belongs to the class of drugs called calcitonin gene-related peptide receptor antagonists. CGRP is a protein in nerve endings responsible for pain and migraines. Ubrogepant blocks this CGRP protein from attachment to the nerve endings, reducing pain and migraine symptoms.

The advantages of the CGRP antagonists are that they are well tolerated and do not cause headaches from medication overuse. They do not have any cardiovascular risk and can be used in patients with cardiovascular disease. The development of Ubrogepant can mark a significant advancement in migraine headache treatment.

What Are the Ingredients in Ubrogepant?

Active Ingredient: Ubrogepant.

Colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, polyvinylpyrrolidone vinyl acetate copolymer, sodium chloride, sodium stearyl fumarate, and vitamin E polyethylene glycol succinate.

Dosage Forms And Strengths of Ubrogepant

• Ubrogepant 50 mg is supplied as white to off-white, capsule-shaped, biconvex tablets debossed with "U50" on one side.

• Ubrogepant 100 mg is supplied as white to off-white, capsule-shaped, biconvex tablets debossed with "U100" on one side.

• Each packet contains one tablet.

For Patients

Why Is Ubrogepant Medication Prescribed?

Ubrogepant treats severe migraine headaches, throbbing headaches, nausea, and sensitivity to sound. Ubrogepant is a group of calcitonin gene-related peptide receptor antagonists. It acts by blocking the action of a natural substance in the body, leading to migraine headaches. However, Ubrogepant cannot prevent migraine episodes or reduce the number of attacks.

How Does Ubrogepant Work?

• Ubrogepant treats migraine headache pain by blocking the transmitter activity involved in migraine.

• Ubrogepant belong to calcitonin gene-related peptide receptor antagonists. Therefore, at a dose two times the maximum recommended daily dose, Ubrogepant does not prolong the QT interval.

• Doses need to be adjusted to avoid increased exposure in patients with hepatic or renal insufficiency, and Ubrogepant is not used in patients with end-stage kidney disorder.

• The current theory of migraine pathophysiology accepts the dysfunction of the central nervous system, particularly the trigeminal ganglion, as the reason for the condition.

How to Administer Ubrogepant 100 MG Tablet?

• Read the patient information guide with the medication before consuming Ubrogepant, and do the same with every refill. If you have any questions, consult the doctor or pharmacist.

• Take Ubrogepant by mouth with or without food and as directed by a doctor at the first migraine episode.

• The dosage is prescribed according to the medical condition, medication response, and other treatment options. Inform the doctor and pharmacist about all the drugs in use. If required, the second tablet can be taken two hours after the first one.

• The second tablet should not be taken within 24 hours after consumption of grapefruit or grapefruit juice. Do not exceed 200 milligrams in 24 hours.

• It is still unclear if Ubrogepant can be taken for more than eight migraines in 30 days.

How Effective Is Ubrogepant for Migraines?

Scientific testing demonstrates how this drug helps reduce both the power and duration of migraine attacks. Patients obtain migraine headache relief through Ubrogepant because the drug turns off calcitonin gene-related peptide (CGRP) protein function. Users of the drug often note a reduction in their headaches when measured shortly after drug consumption, until they begin to report considerable relief. Ubrogepant provides an excellent choice for migraine patients because it maintains a very favorable side-effect profile compared to standard medications. Medical professionals consider Ubrogepant to be an effective solution when searching for strong migraine relief treatment options.

What Precautions Should Be Taken With Ubrogepant?

• Before taking Ubrogepant, be sure to be aware of any other allergies or if you are allergic to it.

• Ubrogepant contains inactive ingredients that can cause allergic reactions.

• Inform the doctor or pharmacist about your medical history of kidney and liver problems.

• This drug can cause drowsiness.

• Avoid driving, using machines, or doing any activity that needs alertness. Limit alcoholic beverage intake. Inform the doctor about the use of marijuana.

• Before surgery, inform the doctor about all the products, prescription, and nonprescription drugs used.

Overdosage

It is very important to call the emergency medical service if you know you may have overdosed on the drug and have severe symptoms. A few of them are passing out or having trouble breathing. They need to be closely monitored for at least 24 hours.

What Are the Tips to Maximize the Effectiveness of Ubrogepant?

Timeliness in an intervention maximizes the efficiency of Ubrogepant in the treatment of migraine attacks. Ubrogepant works best when given a chance from the very onset of symptoms, with the individual trying to live as normally as possible, with hydration, control of stress, and avoidance of recognized triggers, as these would be assumed to have a positive effect on the mechanism of action of the drug. Of course, keeping a headache diary is beneficial in that it documents the person's history of migraine attacks and reveals how that person has done with Ubrogepant, all of which aids significantly in fine-tuning treatment.

What If Ubrogepant Fails to Work?

If Ubrogepant isn't working for your migraine, you need to see a healthcare provider who can further investigate the reasons behind Ubrogepant's ineffectiveness. Dosage adjustments, with or without the introduction of alternative treatments, might be recommended. Do not increase your dose beyond the recommended amount without professional advice, as this can cause further undesirable effects.

You might also want to consider complementary therapies like cognitive behavioral therapy, acupuncture, or making some lifestyle changes, as these could provide extra relief. Keeping a detailed log of your migraine episodes—like when you took your medication and any other treatments you tried—can help your provider figure out the best way to move forward.

For Doctors

What Are the Pharmacological Aspects of Ubrogepant?

Mechanism of Action

• Ubrogepant treats migraine headache pain by blocking the transmitter activity involved in migraine.

• Activation of the trigeminal ganglion triggers and stimulates the trigeminal afferents, which project to the spinal cord and synapse on pain-sensing intracranial and extracranial structures, like the dura mater.

• The pain signals are then received from a relay of second-order ascending neurons, which carry them through to the brainstem, the hypothalamus, and thalamic nuclei before they follow to regions of the cortex, including the auditory, visual, and motor cortices.

• Pain signals can be further propagated through second-order ascending neurons up to the brainstem, hypothalamus, and thalamic nuclei, followed by cortical regions such as the auditory, visual, and motor cortices.

• The trigeminal ganglion amplifies migraine headache pain by activating the perivascular fibers and releasing pain-causing molecules, such as calcitonin gene-related peptide (CGRP).

• The α-isoform of CGRP, present in primary sensory neurons, is a vasodilator associated with migraine pathogenesis. CGRP levels are much higher during migraine attacks, and the levels return to normal post-treatment with triptan medications or intravenous infusions of CGRP, which can trigger migraine-like headaches in some patients. Along with vasodilation, CGRP acts as a pronociceptive factor and modulates neuronal excitability and pain response.

Pharmacodynamics:

• Absorption: Tmax is seen between 0.7 and 1.5 hours after being taken orally. When consumed with a high-fat meal, Tmax is delayed by around two hours, and Cmax reduces by 22 percent. According to the recommended doses, Ubrogepant has dose-related pharmacokinetics.

• The Volume of Distribution: The apparent central volume of distribution after oral administration is 350 L.

• Protein Binding: Ubrogepant is 87 percent protein-bound in vitro; however, the specific proteins to which Ubrogepant binds are unknown.

• Metabolism: Ubrogepant is eliminated mainly by metabolism; CYP3A4 mediates the majority of metabolism. Circulating glucuronide conjugates and unchanged parent drugs are commonly found in plasma circulating components. The glucuronide metabolites carry significantly less activity at CGRP receptors and are considered inert pharmacologically.

• Route of Elimination: The main route of elimination of Ubrogepant is fecal or biliary. Also, renal excretion is minimal - when followed up after administration of only one oral dose to healthy patients, around 42 percent of the dose remained unchanged in the feces, and six percent was unchanged in the urine. Ubrogepant is eliminated through metabolism, primarily by CYP3A4. The parent compound, Ubrogepant, and two glucuronide conjugate metabolites were the prevalent circulating components in human plasma. The glucuronide metabolites, however, do not contribute to the pharmacological activity of Ubrogepant as they are less potent in the CGRP receptor binding assay.

• Half-Life: Ubrogepant has an elimination half-life of around five to seven hours.

• Clearance: The oral clearance of Ubrogepant is around 87 L/h.

• Excretion: The elimination half-life of Ubrogepant is around five to seven hours. The mean oral clearance is 87 L/hr. Ubrogepant is excreted via the biliary or fecal route and the renal route.

• Effect of Food: When Ubrogepant was administered with a high-fat meal, the time to maximum Ubrogepant plasma concentration was delayed by two hours.

• Distribution: The plasma protein binding of Ubrogepant is 87 percent. The mean central volume of distribution of Ubrogepant post-single-dose oral is 350 L.

What Are the Side Effects of Ubrogepant?

• Nausea.

• Drowsiness and sleepiness.

• Allergic reactions to this drug are rare.

• Rash, itching, and swelling.

What Are the Common Interactions of Ubrogepant With Other Drugs?

1. Ketoconazole and Itraconazole.

2. Clarithromycin and Erythromycin.

3. Rifampin and Rifabutin.

4. Carbamazepine and Phenytoin.

5. Verapamil.

6. Cyclosporine.

7. Ciprofloxacin.

8. Fluconazole.

9. Fluvoxamine.

10. Barbiturates.

11. Quinidine.

12. Carvedilol.

13. Eltrombopag.

14. Curcumin.

How to Store and Dispose of Ubrogepant?

Ubrogepant can be stored at room temperature, away from light and moisture. Keep the medication away from children and pets. Do not flush down the drugs or pour them into a drain. Discard the product if it has expired or is no longer needed. Dispose of the products. Keep this medication in a container that is closed tightly and out of sight and reach of kids. Storage should be at room temperature.

Who Should Not Take Ubrogepant?

It is advised not to take Ubrogepant if someone is currently on medicines called CYP3A4 strong inhibitors, like:

• Ketoconazole.

• Clarithromycin.

• Itraconazole.

Clinical Studies

For the treatment of migraine, a randomized controlled trial was carried out by David W Dodick, who gave the following information: Ubrogepant is a small-molecule calcitonin gene-related peptide receptor antagonist used to treat acute migraine. A trial of Ubrogepant was conducted to evaluate its efficacy, safety, and side effects. Adults with migraine, with or without aura, were selected to receive an initial dose of placebo, 50 mg, or Ubrogepant 100 mg for the treatment of a single migraine attack, along with the option to take a second dose. The efficacy was pain relief two hours after the first dose and absence of migraine-associated symptoms at two hours, pain relief at two hours followed by sustained pain relief from 2 to 24 hours, and lack of symptoms associated with migraines like photophobia, phonophobia, and nausea at 2 hours. More participants who received Ubrogepant than those who received a placebo were free from pain, and most of the symptoms occurred two hours after the dose. The commonly reported adverse effects were nausea, somnolence, and dry mouth.

In the clinical experiment, adults with migraine were randomized in controlled groups into the following groups: the Ubrogepant-50 mg or Ubrogepant-100mg group.

Specific Population:

• Pregnancy: There is no documented information available regarding the risk of a human pregnancy to a baby. It is very important that you contact your doctor or physician and inform him or her if you are pregnant or if you are planning to conceive.

• Lactation: No data are available on traces of Ubrogepant in human milk, its effects on the breastfed infant, or its effects on milk production. Inform the doctor about breastfeeding or any plan to breastfeed. It is not clear yet if Ubrogepant can be traced into breast milk.

• Pediatric Use: Safety and effectiveness in pediatric patients have not been established yet.

• Geriatric Use: No clinically significant differences were seen in studies available between old and young subjects.

• Hepatic Impairment: In patients with pre-existing mild, moderate, or severe hepatic impairment, Ubrogepant exposure was increased by 7 %, 50 %, and 115 %, respectively. Dose adjustment is advised for patients only with severe hepatic impairment, not for patients with mild or moderate hepatic impairment.

• Renal Impairment: No dose adjustment is needed in mild or moderate renal impairment cases. However, dose adjustment is necessary for patients with severe renal impairment.

Key Takeaway From iCliniq

Except for an ongoing headache, Ubrogepant is suitable for the focused treatment of acute migraine. When taken at the start of a headache attack, it can indeed be an option to consider, but determining personal triggers and working with your healthcare provider regarding the most effective long-term treatment plan for migraine management is fundamental.